[Bone substitutes].

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 6. Oper Neurosurg. 2021 Jun 15;21(Suppl 1):S2-S9. doi: 10.1093/ons/opaa383. Osteobiologics. Golubovsky JL(1), Ejikeme T(2), Winkelman R(3), Steinmetz MP(4). Author information: (1)Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Education Institute, Cleveland Clinic, Cleveland, Ohio, USA. (2)Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. (3)Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. (4)Center for Spine Health, Department of Neurosurgery, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Comment in Oper Neurosurg. 2021 Jun 15;21(Suppl 1):S10-S11. doi: 10.1093/ons/opaa403. BACKGROUND: Osteobiologics are engineered materials that facilitate bone healing and have been increasingly used in spine surgery. Autologous iliac crest bone grafts have been used historically, but morbidity associated with graft harvesting has led surgeons to seek alternative solutions. Allograft bone, biomaterial scaffolds, growth factors, and stem cells have been explored as bone graft substitutes and supplements. OBJECTIVE: To review current and emerging osteobiologic technologies. METHODS: A literature review of English-language studies was performed in PubMed. Search terms included combinations of "spine," "fusion," "osteobiologics," "autologous," "allogen(e)ic," "graft," "scaffold," "bone morphogenic protein," and "stem cells." RESULTS: Evidence supports allograft bone as an autologous bone supplement or replacement in scenarios where minimal autologous bone is available. There are promising data on ceramics and P-15; however, comparative human trials remain scarce. Growth factors, including recombinant human bone morphogenic proteins (rhBMPs) 2 and 7, have been explored in humans after successful animal trials. Evidence continues to support the use of rhBMP-2 in lumbar fusion in patient populations with poor bone quality or revision surgery, while there is limited evidence for rhBMP-7. Stem cells have been incredibly promising in promoting fusion in animal models, but human trials to this point have only involved products with questionable stem cell content, thereby limiting possible conclusions. CONCLUSION: Engineered stem cells that overexpress osteoinductive factors are likely the future of spine fusion, but issues with applying viral vector-transduced stem cells in humans have limited progress. © Congress of Neurological Surgeons 2021. DOI: 10.1093/ons/opaa383